Safety and Efficacy of the SHURUI Single-Port Robot-Assisted System via Transmesenteric Approach for Pyeloplasty in Upper Ureteral Stricture: A Single-Center Prospective Cohort Study.

Authors

Jiyu Yang, Bing Wang, Linsong Yang, Wenzhi Gao, Zihui Gao, Zhihua Li, Yaming Gu, Xuesong Li, Kunlin Yang

Published in

International braz j urol : official journal of the Brazilian Society of Urology. Volume 52. Issue 6.

Abstract

Pyeloplasty is an established procedure for proximal ureteral strictures, with proven feasibility and favorable outcomes (1). The single-port robotic system offers potential advantages such as reduced invasiveness and improved cosmesis (2, 3), while the transmesenteric approach provides direct retroperitoneal access with minimal colonic mobilization (4, 5). However, the combination of single-port robotic platform with transmesenteric approach for pyeloplasty remains scarcely reported. This study aims to evaluate the safety and efficacy of this combined technique using the SHURUI single-port robotic surgical system.
From June 2024 to March 2025, 8 patients with upper ureteral stricture underwent robotic pyeloplasty via transmesenteric approach using the SHURUI single-port system. Demographic, perioperative, and follow-up data were prospectively collected. Clinical success was defined as symptom-free with no radiographic evidence of obstruction.
All surgeries were successfully completed without any conversion to laparoscopic or open procedures. The median docking time and console time were 4 (IQR: 2-8) min and 125 (IQR: 113-157) min, respectively. The median estimated blood loss was 10 (IQR: 10-10) ml, and none of the patients required intraoperative transfusion. The median postoperative stay was 4 (IQR: 3-6) days, with no complications occurring. With a median follow-up of 15 (IQR: 11-17) months, all patients achieved clinical success.
The SHURUI single-port robotic system is safe and effective for pyeloplasty in upper ureteral stricture via transmesenteric approach. Further validation through multi-center studies with larger cohorts and longer-term follow-up is recommended.

PMID:
42397985
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.